A Review of Issues Affecting the Efficiency of Decision Making in the NICE Single Technology Appraisal Process

Matthew Walton1, Joanne O’Connor1, Christopher Carroll2, Lindsay Claxton1, Robert Hodgson1
1Centre for Reviews and Dissemination, University of York, York, UK
2School of Health and Related Research, University of Sheffield, Sheffield, UK

Tóm tắt

Từ khóa


Tài liệu tham khảo

National Institute for Health and Care Excellence. Guide to the processes of technology appraisal. NICE. 2018. https://www.nice.org.uk/process/pmg19/chapter/acknowledgements . Accessed 1 Jul 2018.

National Institute for Health and Care Excellence. Proposals for increasing capacity within NICE’s technology appraisal programme. NICE. 2017. https://www.nice.org.uk/Media/Default/About/what-we-do/our-programmes/technology-appraisals/increasing-ta-capacity-consultation.pdf . Accessed 21 Dec 2017.

Yan L, Zhang W. Precision medicine becomes reality—tumour type agnostic-therapy. Cancer Commun. 2018;38(6).

National Institute for Health and Care Excellence, NHS England. Consultation on changes to technology appraisals and highly specialised technologies. NHS England. 2017.

Carroll C, Houten R, Boland A, Kaltenthaler E, Dickson R. What is the evidence from past National Institute of Health and Care Excellence Single-Technology Appraisals regarding company submissions with base-case incremental cost-effectiveness ratios of less than £10,000/QALY? Value Health. 2017;21:341–50.

Kaltenthaler E, Carroll C, Hill-McManus D, Scope A, Holmes M, Rice S, Rose M, Tappenden P, Woolacott N. Issues related to the frequency of exploratory analyses by Evidence Review Groups in the NICE Single Technology Appraisal process. PharmacoEconomics Open. 2016;1:99–108.

Dillon A, Landells LJ. NICE, the NHS, and Cancer Drugs. JAMA. 2018;319(8):767–8.

Cerri KH, Knapp M, Ferández JL. Decision making by NICE: examining the influences of evidence, process and context. Health Econ Policy Law. 2014;9(2):119–41.

Dakin H, Devlin N, Feng Y, Rice N, O’Neill P, Parkin D. The influence of cost-effectiveness and other factors on NICE decisions. Health Econ. 2015;24:1256–71.

National Audit Office. Investigation into the Cancer Drugs Fund: National Audit Office. 2015. https://www.nao.org.uk/wp-content/uploads/2015/09/Investigation-into-the-Cancer-Drugs-Fund1.pdf . Accessed 5 May 2018.

NHS England Cancer Drugs Fund Team. Appraisal and funding of cancer drugs from July 2016 (including the new Cancer Drugs Fund) - a new deal for patients, taxpayers and industry. NHS England. 2016. https://www.england.nhs.uk/wp-content/uploads/2013/04/cdf-sop.pdf . Accessed 20 May 2018.

Akehurst RL, Abadie E, Renaudin N, Sarkozy F. Variation in health technology assessment and reimbursement processes in Europe. Value Health. 2017;20:67–76.

Clement FM, Harris A, Li JJ, Yong K, Lee KM, Manns BJ. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada. JAMA. 2009;302(13):1437–43.